Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | -34.20% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.31 | N/A | -34.20% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance and the lack of guidance indicates uncertainty. They highlighted ongoing efforts to improve operations.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability in the near term.
BioCryst Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a 9% decline in stock price. The absence of revenue figures and guidance adds to investor uncertainty. The management's defensive tone suggests that the company may face challenges ahead, impacting investor confidence.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SYSCO CORP
May 2, 2016